Tislelizumab plus chemo for nasopharyngeal cancer with bone spread
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of the immunotherapy drug tislelizumab with chemotherapy for people whose nasopharyngeal cancer has spread to the bones. It may be an option if you have not had prior treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have nasopharyngeal cancer that has spread to the bones (and possibly other places, but not measurable tumors elsewhere).
- You must not have received any chemotherapy or immunotherapy for advanced disease before; any past treatment must have ended more than 6 months ago.
- You must be in generally good health, able to care for yourself, and have adequate organ function.
- You must not have certain autoimmune diseases, active infections, or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This study compares two combinations of drugs (tislelizumab plus either GX or GP) to see which works better for people with nasopharyngeal cancer that has returned or spread and has not been treated with systemic therapy before.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
This study tests two immunotherapy drugs together for people whose nasopharyngeal cancer has continued to grow after standard treatments. The goal is to see if this combination can help shrink or slow the cancer.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.